跳至主要内容
临床试验/NCT00467467
NCT00467467已完成3 期

Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

University of Minnesota2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年6月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
60
试验地点
2
主要终点
effect of study medication on urinary symptoms and quality of life

研究概览

简要总结

To assess the impact of alfuzosin vs. placebo on ureteral stent discomfort, urinary symptoms and quality of life.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Undergoing unilateral retrograde ureteroscopy with ureteral stent placement

排除标准

  • Significant ureteral trauma
  • Concomitant ESWL or other secondary surgical procedure than may impact patient comfort
  • Subject with know hypersensitivity to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets.
  • Pregnancy, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study
  • Undergoing bilateral ureteral stenting
  • Undergoing antegrade ureteral stenting
  • Undergoing simultaneous extracorporeal shockwave lithotripsy
  • Urinary infection (fever >101, positive urine culture, many bacteria on urinalysis)
  • Primary bladder dysfunction that would impact ability to void without a catheter
  • Neurologic dysfunction that would impair pain sensation
  • History of chronic pain or substance abuse
  • Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased
  • Other alpha-blockers
  • Phosphodiesterase type 5 inhibitors for erectile function Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study.

结局指标

主要结局

effect of study medication on urinary symptoms and quality of life

usage of analgesics/narcotics

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验